H
Hashem O. Alsaab
Researcher at Taif University
Publications - 85
Citations - 2728
Hashem O. Alsaab is an academic researcher from Taif University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 17, co-authored 46 publications receiving 1678 citations. Previous affiliations of Hashem O. Alsaab include Wayne State University & University of Toledo.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O. Alsaab,Hashem O. Alsaab,Samaresh Sau,Rami Alzhrani,Rami Alzhrani,Katyayani Tatiparti,Ketki Bhise,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +10 more
TL;DR: The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.
Journal ArticleDOI
Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery
Ashok Kumar Sharma,Avinash Gothwal,Prashant Kesharwani,Hashem O. Alsaab,Arun K. Iyer,Arun K. Iyer,Umesh Gupta +6 more
TL;DR: This review highlights recent advances in the delivery of anticancer drugs using dendrimers, as well as other biomedical and diagnostic applications that have a significant positive impact on the growing arena of drug delivery and targeting.
Journal ArticleDOI
Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.
Jennifer M. Wickens,Hashem O. Alsaab,Prashant Kesharwani,Ketki Bhise,Mohd Cairul Iqbal Mohd Amin,Rakesh K. Tekade,Umesh Gupta,Arun K. Iyer,Arun K. Iyer +8 more
TL;DR: In vitro and in vivo experiments have repeatedly indicated HA-based nanocarriers to be a target-specific drug and gene delivery platform with great promise for future applications in clinical cancer therapy.
Journal ArticleDOI
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Samaresh Sau,Hashem O. Alsaab,Ketki Bhise,Rami Alzhrani,Ghazal Nabil,Arun K. Iyer,Arun K. Iyer +6 more
TL;DR: The role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy and the function of host immune stimulatory signals and tumor immunotherapies can be improved by repurposing of nanomedicine platform are summarized.
Journal ArticleDOI
Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
Samaresh Sau,Hashem O. Alsaab,Sushil K. Kashaw,Katyayani Tatiparti,Arun K. Iyer,Arun K. Iyer +5 more
TL;DR: With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy and ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.